Paracoccidioidomicose

Desafios no desenvolvimento de uma vacina contra micose endêmica nas Américas

Translated title of the contribution: Paracoccidioidomycosis: Challenges in the development of a vaccine against an endemic mycosis in the Americas

Carlos P. Taborda, M. E. Urán, Joshua D. Nosanchuk, L. R. Travassos

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Paracoccidioidomycosis (PCM), caused by Paracoccidioides spp, is an important endemic mycosis in Latin America. There are two recognized Paracoccidioides species, P. brasiliensis and P. lutzii, based on phylogenetic differences; however, the pathogenesis and disease manifestations of both are indistinguishable at present. Approximately 1,853 (~51,2%) of 3,583 confirmed deaths in Brazil due to systemic mycoses from 1996-2006 were caused by PCM. Antifungal treatment is required for patients with PCM. The initial treatment lasts from two to six months and sulfa derivatives, amphotericin B, azoles and terbinafine are used in clinical practice; however, despite prolonged therapy, relapses are still a problem. An effective Th1-biased cellular immune response is essential to control the disease, which can be induced by exogenous antigens or modulated by prophylactic or therapeutic vaccines. Stimulation of B cells or passive transference of monoclonal antibodies are also important means that may be used to improve the efficacy of paracoccidioidomycosis treatment in the future. This review critically details major challenges facing the development of a vaccine to combat PCM.

Original languageUndefined
Pages (from-to)21-24
Number of pages4
JournalRevista do Instituto de Medicina Tropical de Sao Paulo
Volume57
DOIs
StatePublished - Sep 1 2015

Fingerprint

Paracoccidioidomycosis
Mycoses
Vaccines
Paracoccidioides
terbinafine
Azoles
Latin America
Amphotericin B
Therapeutics
Cellular Immunity
Brazil
B-Lymphocytes
Monoclonal Antibodies
Antigens
Recurrence

Keywords

  • Immunoprotection
  • Paracoccidioides brasiliensis
  • Paracoccidioides lutzii
  • Peptide P10
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Paracoccidioidomicose : Desafios no desenvolvimento de uma vacina contra micose endêmica nas Américas. / Taborda, Carlos P.; Urán, M. E.; Nosanchuk, Joshua D.; Travassos, L. R.

In: Revista do Instituto de Medicina Tropical de Sao Paulo, Vol. 57, 01.09.2015, p. 21-24.

Research output: Contribution to journalArticle

@article{afc4200d4bb7409b93f6b062405ff710,
title = "Paracoccidioidomicose: Desafios no desenvolvimento de uma vacina contra micose end{\^e}mica nas Am{\'e}ricas",
abstract = "Paracoccidioidomycosis (PCM), caused by Paracoccidioides spp, is an important endemic mycosis in Latin America. There are two recognized Paracoccidioides species, P. brasiliensis and P. lutzii, based on phylogenetic differences; however, the pathogenesis and disease manifestations of both are indistinguishable at present. Approximately 1,853 (~51,2{\%}) of 3,583 confirmed deaths in Brazil due to systemic mycoses from 1996-2006 were caused by PCM. Antifungal treatment is required for patients with PCM. The initial treatment lasts from two to six months and sulfa derivatives, amphotericin B, azoles and terbinafine are used in clinical practice; however, despite prolonged therapy, relapses are still a problem. An effective Th1-biased cellular immune response is essential to control the disease, which can be induced by exogenous antigens or modulated by prophylactic or therapeutic vaccines. Stimulation of B cells or passive transference of monoclonal antibodies are also important means that may be used to improve the efficacy of paracoccidioidomycosis treatment in the future. This review critically details major challenges facing the development of a vaccine to combat PCM.",
keywords = "Immunoprotection, Paracoccidioides brasiliensis, Paracoccidioides lutzii, Peptide P10, Vaccine",
author = "Taborda, {Carlos P.} and Ur{\'a}n, {M. E.} and Nosanchuk, {Joshua D.} and Travassos, {L. R.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1590/S0036-46652015000700005",
language = "Undefined",
volume = "57",
pages = "21--24",
journal = "Revista do Instituto de Medicina Tropical de Sao Paulo",
issn = "0036-4665",
publisher = "Instituto de Medicina Tropical de Sao Paulo",

}

TY - JOUR

T1 - Paracoccidioidomicose

T2 - Desafios no desenvolvimento de uma vacina contra micose endêmica nas Américas

AU - Taborda, Carlos P.

AU - Urán, M. E.

AU - Nosanchuk, Joshua D.

AU - Travassos, L. R.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Paracoccidioidomycosis (PCM), caused by Paracoccidioides spp, is an important endemic mycosis in Latin America. There are two recognized Paracoccidioides species, P. brasiliensis and P. lutzii, based on phylogenetic differences; however, the pathogenesis and disease manifestations of both are indistinguishable at present. Approximately 1,853 (~51,2%) of 3,583 confirmed deaths in Brazil due to systemic mycoses from 1996-2006 were caused by PCM. Antifungal treatment is required for patients with PCM. The initial treatment lasts from two to six months and sulfa derivatives, amphotericin B, azoles and terbinafine are used in clinical practice; however, despite prolonged therapy, relapses are still a problem. An effective Th1-biased cellular immune response is essential to control the disease, which can be induced by exogenous antigens or modulated by prophylactic or therapeutic vaccines. Stimulation of B cells or passive transference of monoclonal antibodies are also important means that may be used to improve the efficacy of paracoccidioidomycosis treatment in the future. This review critically details major challenges facing the development of a vaccine to combat PCM.

AB - Paracoccidioidomycosis (PCM), caused by Paracoccidioides spp, is an important endemic mycosis in Latin America. There are two recognized Paracoccidioides species, P. brasiliensis and P. lutzii, based on phylogenetic differences; however, the pathogenesis and disease manifestations of both are indistinguishable at present. Approximately 1,853 (~51,2%) of 3,583 confirmed deaths in Brazil due to systemic mycoses from 1996-2006 were caused by PCM. Antifungal treatment is required for patients with PCM. The initial treatment lasts from two to six months and sulfa derivatives, amphotericin B, azoles and terbinafine are used in clinical practice; however, despite prolonged therapy, relapses are still a problem. An effective Th1-biased cellular immune response is essential to control the disease, which can be induced by exogenous antigens or modulated by prophylactic or therapeutic vaccines. Stimulation of B cells or passive transference of monoclonal antibodies are also important means that may be used to improve the efficacy of paracoccidioidomycosis treatment in the future. This review critically details major challenges facing the development of a vaccine to combat PCM.

KW - Immunoprotection

KW - Paracoccidioides brasiliensis

KW - Paracoccidioides lutzii

KW - Peptide P10

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84944458449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944458449&partnerID=8YFLogxK

U2 - 10.1590/S0036-46652015000700005

DO - 10.1590/S0036-46652015000700005

M3 - Article

VL - 57

SP - 21

EP - 24

JO - Revista do Instituto de Medicina Tropical de Sao Paulo

JF - Revista do Instituto de Medicina Tropical de Sao Paulo

SN - 0036-4665

ER -